NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · INSM · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Insmed Incorporated’s quoted price sits in the lower half of its reported 52-week range, 47.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Insmed Incorporated’s next earnings report is currently expected on Feb 18, 2027, with estimated earnings per share of -$0.26. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Insmed Incorporated’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:42 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Aug 7, 2025 | -$1.70-30.77% vs estimate | $107.42M+3.16% vs estimate |
|---|
| Q1 2025 | May 8, 2025 | -$1.42-5.97% vs estimate | $92.82M+1.48% vs estimate |
|---|
| Q4 2024 | Feb 20, 2025 | -$1.32-12.82% vs estimate | $104.44M+2.31% vs estimate |
|---|
THE ANALYST VIEW
36 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 16 contributors · Median target $193.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$593.54+$7.06 (+1.2%)
United Therapeutics Corporation’s quoted price sits in the upper half of its reported 52-week range, 2.59% below the high.
$44.99-$0.73 (-1.6%)
Liquidia Corporation’s quoted price sits in the lower half of its reported 52-week range, 51.94% below the high.
$25.71-$0.03 (-0.12%)
Avalyn Pharma Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 36.0% below the high.
$17.03$0.00 (0.0%)
Theravance Biopharma Inc’s quoted price sits in the lower half of its reported 52-week range, 19.02% below the high.
